Cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-19. Numbers and descriptions here follow the published literature rather than marketing material.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
In biology, a pair bond is the strong affinity that develops in some species between a mating pair, often leading to the production and rearing of young and potentially a lifelong bond. Pair-bonding is a term coined in the 1940s that is frequently used in sociobiology and evolutionary biology circles. The term often implies either a lifelong socially monogamous relationship or a stage of mating interaction in socially monogamous species. It is sometimes used in reference to human relationships.
I reject only the concept that black liberation can be achieved through the leadership of white liberals." He added that "the [white] liberal is no enemy, he's a friend – but for the moment he holds us back, offering a formula too gentle, too inadequate for our struggle". Biko's approach to activism focused on psychological empowerment, and both he and the BCM saw their main purpose as combating the feeling of inferiority that most black South Africans experienced. Biko expressed dismay at how "the black man has become a shell, a shadow of man ... bearing the yoke of oppression with sheepish timidity", and stated that "the most potent weapon in the hands of the oppressor is the mind of the oppressed". He believed that blacks needed to affirm their own humanity by overcoming their fears and believing themselves worthy of freedom and its attendant responsibilities. He defined Black Consciousness as "an inward-looking process" that would "infuse people with pride and dignity". To promote this, the BCM adopted the slogan "Black is Beautiful". One of the ways that Biko and the BCM sought to achieve psychological empowerment was through community development. Community projects were seen not only as a way to alleviate poverty in black communities but also as a means of transforming society psychologically, culturally, and economically. They would also help students to learn about the "daily struggles" of ordinary black people and to spread Black Consciousness ideas among the population.
The antigens are memorised by these cells so that subsequent exposure to the same type of antigens will stimulate a secondary response, in which a higher concentration of antibodies specific for the antigens are reproduced rapidly and efficiently in a short time for the elimination of the pathogen. Under specific circumstances, low doses of vaccines are given initially, followed by additional doses named booster doses. Boosters can effectively maintain the level of memory cells in the human body, hence extending a person's immunity.
John Ronald Reuel Tolkien was born on 3 January 1892 in Bloemfontein in the Orange Free State (later annexed by the British Empire; now Free State Province in the Republic of South Africa), to Arthur Reuel Tolkien, an English bank manager, and his wife Mabel, née Suffield. The couple had left England when Arthur was promoted to head the Bloemfontein office of the British bank for which he worked. Tolkien had one sibling, his younger brother, Hilary Arthur Reuel Tolkien, who was born on 17 February 1894. As a child Tolkien was bitten by a large baboon spider in the garden, an event some believe to have been later echoed in his stories, although he admitted no actual memory of the event as an adult. In an earlier incident from Tolkien's infancy, a young family servant took the baby to his homestead, returning him the next morning. When he was three, he went to England with his mother and brother on what was intended to be a lengthy family visit, but his father died in South Africa of rheumatic fever before he could join them. This left the family without an income, so Tolkien's mother took him to live with her parents in Kings Heath, Birmingham. Soon after, in 1896, they moved to Sarehole (now in Hall Green), then a Worcestershire village, later annexed to Birmingham. He enjoyed exploring Sarehole Mill and Moseley Bog and the Clent, Lickey and Malvern Hills, which would later inspire scenes in his books, along with nearby towns and villages such as Bromsgrove, Alcester and Alvechurch and places such as his aunt Jane's farm Bag End, the name of which he used in his fiction.
==== Group B – Acetonides (and related substances) ==== Amcinonide, budesonide, desonide, fluocinolone acetonide, fluocinonide, halcinonide, triamcinolone acetonide, and Deflazacort (O-isopropylidene derivative)
Sources: en.wikipedia.org
Arsenic trioxide, even at low concentrations, causes the degradation of PML/RARα, thereby partially restoring the differentiation of cancerous promyelocytes. Arsenic trioxide activates JNK (c-Jun N-terminal kinase), also known as stress-activated protein kinase, which belongs to the MAPK (mitogen-activated protein kinase) family. These enzymes play a crucial role in signal transduction within the cell. Under normal conditions, JNK is activated by the phosphorylation of threonine and tyrosine residues. However, studies on specific cell lines derived from patients with acute promyelocytic leukemia have demonstrated that this activation also occurs in response to arsenic trioxide. It seems that the activation of JNK leads to the phosphorylation of both anti-apoptotic proteins (Bcl-2, Bcl-Xl) and pro-apoptotic proteins – Bax (Bcl-2-associated X protein), Bak (Bcl-2 homologous killer), and Bid (BH3 interacting domain death agonist) – effectively activating them. Pro-apoptotic proteins contain the BH3 domain, which is responsible for their "death-inducing" activity. They cause the formation of ion channels in the mitochondrial membrane, resulting in the release of the aforementioned apoptotic factors into the cytoplasm. Anti-apoptotic proteins owe their function to a hydrophobic cleft in their spatial structure that binds to the BH3 domain, thereby neutralizing the effects of the "death" proteins. Under normal conditions, the decision for a cell to undergo apoptosis depends on the ratio of pro-apoptotic to anti-apoptotic proteins.
== Motivation == FTIR is a method of measuring infrared absorption and emission spectra. For a discussion of why people measure infrared absorption and emission spectra, i.e. why and how substances absorb and emit infrared light, see the article: Infrared spectroscopy.
Krieg, Reimar; Jortzik, Esther; Goetz, Alice-Anne; Blandine, Stèphanie; Wittlin, Sergio; Elhabiri, Mourad; Rahbari, Mahsa; Nuryyeva, Selbi; Voigt, Kerstin; Dahse, Hans-Martin; Brakhage, Axel; Beckmann, Svenja; Quack, Thomas; Grevelding, Christoph G.; Pinkerton, Anthony B.; Schönecker, Bruno; Burrows, Jeremy; Davioud-Charvet, Elisabeth; Rahlfs, Stefan; Becker, Katja: Arylmethylamino steroids as antiparasitic agents. Nature Communications 8:14478, 2017. doi: 10.1038/ncomms14478.
The Aviation Safety Reporting System (ASRS) collects voluntarily submitted aviation safety incident/situation reports from pilots, controllers and others. The ASRS uses reports to identify system deficiencies, issue alert messages, and produce two publications, CALLBACK, and ASRS Directline. The collected information is made available to the public, and is used by the FAA, NASA and other organizations working in research and flight safety.
Sources: en.wikipedia.org
=== Radioactivity === Thorium was first observed to be radioactive in 1898, by the German chemist Gerhard Carl Schmidt and later that year, independently, by the Polish-French physicist Marie Curie. It was the second element that was found to be radioactive, after the 1896 discovery of radioactivity in uranium by French physicist Henri Becquerel. Starting from 1899, the New Zealand physicist Ernest Rutherford and the American electrical engineer Robert Bowie Owens studied the radiation from thorium; initial observations showed that it varied significantly. It was determined that these variations came from a short-lived gaseous daughter of thorium, which they found to be a new element. This element is now named radon, the only one of the rare radioelements to be discovered in nature as a daughter of thorium rather than uranium. After accounting for the contribution of radon, Rutherford, now working with the British physicist Frederick Soddy, showed how thorium decayed at a fixed rate over time into a series of other elements in work dating from 1900 to 1903. This observation led to the identification of the half-life as one of the outcomes of the alpha particle experiments that led to the disintegration theory of radioactivity. The biological effect of radiation was discovered in 1903. The newly discovered phenomenon of radioactivity excited scientists and the general public alike. In the 1920s, thorium's radioactivity was promoted as a cure for rheumatism, diabetes, and sexual impotence.
== Mechanism of action == Like other sulfonylureas, chlorpropamide acts to increase the secretion of insulin, so it is only effective in patients who have some pancreatic beta cell function. It can cause relatively long episodes of hypoglycemia; this is one reason why shorter-acting sulfonylureas such as gliclazide or tolbutamide are used instead. The risk of hypoglycemia makes this drug a poor choice for the elderly and patients with mild to moderate hepatic and renal impairment. Chlorpropamide is also used in partial central diabetes insipidus.
=== Aerial capabilities === The Houthis exert partial control over the Yemeni Air Force, and possess key air bases such as Al-Dailami and Al Hudaydah. The Houthi air force consists of a single Northrop F-5 fighter jet, which was seized from the Yemeni government. The group also flew a Soviet-era Mikoyan MiG-29 during a military parade over Sanaa in 2023. They also operate Mil Mi-17 helicopters seized during the civil war.
To promote better consistency between a trial's objective and analysis methods, the International Committee for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) has published a new international trial regulatory guidance in Nov 2019, the ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials. The guidance calls for clearly defining the research question of a trial by specifying its estimand. An estimand is a clear description of the treatment effect a trial aims to quantify. The guidance provides a structured framework for defining estimands, which consists of five attributes: (i) population of patients; (ii) treatment conditions being compared; (iii) the endpoint; (iv) the summary measure; and (v) how intercurrent events are handled. Tutorials on how to implement the estimand framework is available.
=== Peptide synthesis/ACTH === The first chemical synthesis of an active peptide hormone, the nine amino acid cyclic peptide, oxytocin, was achieved in 1954 by du Vigneaud for which he was awarded the Nobel Prize. At the same time, the isolation and structure determination of the anterior pituitary hormone, ACTH, was being pursued in three laboratories. The peptide was eventually determined to be 39 amino acids in length, however enzymatic and mild acid cleavage suggested that a structure comprising only the first 24 amino acids had full biological activity. It was apparent from the outset that ACTH contained the amino acid Arginine and thus methods had to be developed for the incorporation of this basic amino acid into peptides. Hofmann and his group set about this task. Their efforts led to the synthesis of the melanocyte stimulating hormone, β-MSH, which corresponds to the first 13 amino acids of ACTH and to the synthesis of a fully active ACTH peptide corresponding to the amino acid sequence of the first 23 amino acids. In the course of the peptide synthetic work on ACTH, a novel chain cleavage was observed at an acyl-proline linkage while removing protecting groups using metallic sodium in liquid ammonia. This unexpected reaction has subsequently proved useful in special analytical cases.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.